Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

• Results Overview

  Abrocitinib, a daily oral medication, showed manageable safety for long-term use in treating moderate-to-severe eczema, though some side effects like nausea, headache, and infections were observed at different rates depending on the dose.

• Study Summary

  Num Participants:

  2,856

  Study Type:

  Review

  Control Group:

  Placebo

  Efficacy End Points Treatment:

  None

  Efficacy End Points Control:

  None

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Nausea	Low	14.6
  Headache	Low	7.8
  Acne	Low	4.7
  Herpes Zoster	Medium	4.34
  Serious Infection	High	2.33

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected
  Nausea	Low	2.0
  Headache	Low	3.5
  Acne	Low